Connor, Clark & Lunn Investment Management (CC&L)’s Filana Therapeutics FLNA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$231K	Buy	136,931 +36,354	+36%	+$74.8K	﹤0.01%	1459
2025 Q4	$199K	Buy	+100,577	New	+$322K	﹤0.01%	1450
2021 Q4	–	Sell	-6,137	Closed	-$381K	–	1184
2021 Q3	$381K	Buy	+6,137	New	+$512K	﹤0.01%	825
2017 Q2	–	Sell	-4,486	Closed	-$28K	–	928
2017 Q1	$28K	Hold	4,486	–	–	﹤0.01%	881
2016 Q4	$18K	Hold	4,486	–	–	﹤0.01%	869
2016 Q3	$31K	Sell	4,486 -314	-7%	-$5.2K	﹤0.01%	815
2016 Q2	$74K	Sell	4,800 -329	-6%	-$5.22K	﹤0.01%	819
2016 Q1	$80K	Sell	5,129 -142	-3%	-$1.84K	﹤0.01%	777
2015 Q4	$65K	Hold	5,271	–	–	﹤0.01%	773
2015 Q3	$68K	Buy	+5,271	New	+$66.5K	﹤0.01%	681
2014 Q1	–	Sell	-2,086	Closed	-$75K	–	765
2013 Q4	$75K	Buy	+2,086	New	+$55.4K	﹤0.01%	704

Other funds holding FLNA

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s FLNA Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Filana Therapeutics (FLNA) stake by 36% in Q1 2026, buying an estimated $74.8K and bringing the position to 136,931 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #1459.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in FLNA in Q4 2013 and has held it in 11 quarters since. The position peaked at $381K in Q3 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 136,931 shares of Filana Therapeutics worth $231K as of Q1 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 36,354 Filana Therapeutics shares in Q1 2026, an estimated $74.8K.
Filana Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1459 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Filana Therapeutics in Q4 2013 and has held it in 11 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Filana Therapeutics position peaked at $381K in Q3 2021.
101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.